{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:26:51Z","timestamp":1786217211596,"version":"build-2736575974"},"reference-count":24,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The phase 3 SELENE study evaluated ibrutinib\u00a0+ chemoimmunotherapy (CIT; bendamustine and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL). Adult patients who had received \u22651 prior line of CIT were randomized 1:1 to oral ibrutinib (560\u00a0mg) or placebo daily, plus 6 cycles of BR\/R-CHOP. The primary end point was investigator-assessed progression-free survival (PFS). Overall, 403 patients were randomized to ibrutinib\u00a0+ CIT (n\u00a0= 202) or placebo\u00a0+ CIT (n\u00a0= 201). Most patients received BR (90.3%) and had FL (86.1%). With a median follow-up of 84\u00a0months, median PFS was 40.5\u00a0months in the ibrutinib\u00a0+ CIT arm and 23.8\u00a0months in the placebo\u00a0+ CIT arm (hazard ratio [HR], 0.806; 95% confidence interval [CI], 0.626-1.037; P\u00a0= .0922). Median overall survival was not reached in either arm (HR, 0.980; 95%\u00a0CI, 0.686-1.400). Grade \u22653 treatment-emergent adverse events (TEAEs) were reported in 85.6% and 75.4% of patients in the ibrutinib\u00a0+ CIT and placebo\u00a0+ CIT arms, respectively. In each arm, 13 patients had TEAEs leading to death. The addition of ibrutinib to CIT did not significantly improve PFS compared with placebo\u00a0+ CIT. The safety profile was consistent with known profiles of ibrutinib and CIT. This trial was registered at www.clinicaltrials.gov as #NCT01974440.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010298","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T22:04:25Z","timestamp":1695074665000},"page":"7141-7150","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[{"name":"1Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-5688","authenticated-orcid":false,"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"2Hematology Department, Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-3153","authenticated-orcid":false,"given":"Miguel A.","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Fundaleu, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[{"name":"4Department of Clinical Oncology, Maritime Hospital in Gdynia, Gdynia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Freeman","sequence":"additional","affiliation":[{"name":"5Northern Haematology and Oncology Arm, Sydney Adventist Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro Martin","family":"Garc\u00eda-Sancho","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital Universitario de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer de Salamanca-Instituto Universitario de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Glazunova","sequence":"additional","affiliation":[{"name":"7SP Botkin City Clinical Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[{"name":"8Department of Clinical Haematology, Austin Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Zhou","family":"Hou","sequence":"additional","affiliation":[{"name":"9University of Pittsburgh Medical Center, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-412X","authenticated-orcid":false,"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Universitair Ziekenhuis Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvenyslava","family":"Masliak","sequence":"additional","affiliation":[{"name":"12Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-9730","authenticated-orcid":false,"given":"Pam","family":"McKay","sequence":"additional","affiliation":[{"name":"13The Beatson West of Scotland Cancer Centre, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-7883","authenticated-orcid":false,"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[{"name":"14Hematology, Azienda Unit\u00e0 Sanitaria Locale - Istituti di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-0656","authenticated-orcid":false,"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[{"name":"15Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"16Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-1918","authenticated-orcid":false,"given":"Muhit","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Preis","sequence":"additional","affiliation":[{"name":"18Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"19State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"20Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Rowe","sequence":"additional","affiliation":[{"name":"21Janssen Research & Development, High Wycombe, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monelle","family":"Tamegnon","sequence":"additional","affiliation":[{"name":"22Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qin","sequence":"additional","affiliation":[{"name":"22Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Henninger","sequence":"additional","affiliation":[{"name":"22Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeliene","family":"Curtis","sequence":"additional","affiliation":[{"name":"21Janssen Research & Development, High Wycombe, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donne Bennett","family":"Caces","sequence":"additional","affiliation":[{"name":"22Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"23Hemato-Oncology Department, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"24Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"issue":"1","key":"2023112822312056500_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00277-018-3501-8","article-title":"Burden of illness of follicular lymphoma and marginal zone lymphoma","volume":"98","author":"Monga","year":"2019","journal-title":"Ann Hematol"},{"issue":"S1","key":"2023112822312056500_bib2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5045\/br.2022.2022054","article-title":"Treatment of indolent lymphoma","volume":"57","author":"Jeong","year":"2022","journal-title":"Blood Res"},{"key":"2023112822312056500_bib3","first-page":"1","article-title":"Revising the treatment pathways in lymphoma: new standards of care \u2013 how do we choose?","volume":"42","author":"Ngu","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2023112822312056500_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2018.1.189","article-title":"Sequencing of therapies in relapsed follicular lymphoma","volume":"2018","author":"Nastoupil","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"suppl 2","key":"2023112822312056500_bib5","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1016\/S2152-2650(22)01563-4","article-title":"IBCL-425 disease burden and treatment patterns of relapsed\/refractory follicular lymphoma: a systematic literature review","volume":"22","author":"Chang","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2023112822312056500_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"3","key":"2023112822312056500_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"2023112822312056500_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"2023112822312056500_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2023112822312056500_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"2023112822312056500_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"2023112822312056500_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023112822312056500_bib13","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.4588","article-title":"The outcome of watchful waiting in patients with previously treated follicular lymphoma","volume":"11","author":"Fujino","year":"2022","journal-title":"Cancer Med"},{"issue":"7","key":"2023112822312056500_bib14","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1097\/HS9.0000000000000745","article-title":"A\u00a0retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)","volume":"6","author":"Salles","year":"2022","journal-title":"Hemasphere"},{"issue":"23","key":"2023112822312056500_bib15","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2023112822312056500_bib16","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2023112822312056500_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A\u00a0phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2023112822312056500_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023112822312056500_bib19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023112822312056500_bib20","first-page":"148","article-title":"Treatment patterns and health care costs in commercially insured patients with follicular lymphoma","volume":"7","author":"Fowler","year":"2020","journal-title":"J\u00a0Health Econ Outcomes Res"},{"issue":"14","key":"2023112822312056500_bib21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023112822312056500_bib22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"2023112822312056500_bib23","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"2023112822312056500_bib24","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/j.annonc.2021.08.119","article-title":"Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial","volume":"32","author":"\u00d6zcan","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7141\/2109950\/blooda_adv-2023-010298-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7141\/2109950\/blooda_adv-2023-010298-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T22:31:36Z","timestamp":1701210696000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/7141\/497951\/Phase-3-SELENE-study-ibrutinib-plus-BR-R-CHOP-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":24,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010298","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}